Unveiling the Prognostic Role of Synaptophysin in Conventional Colorectal Carcinomas.

Introduction: Although neuroendocrine differentiation in colorectal carcinomas (CRCs) has been extensively reported, the biological behavior of adenocarcinomas expressing synaptophysin (Syn) but lacking typical neuroendocrine morphology remains unclear.

Methods: We tested 663 conventional CRCs with non-neuroendocrine morphology for Syn expression and correlated the results with clinicopathological and molecular characteristics as well as patient survival (overall survival [OS] and disease-free survival [DFS]). The survival characteristics of Syn expression group were compared to those of conventional CRCs and subsequently to those of 14 MiNENs.

Results: Syn immunohistochemical expression ≥30% was confirmed in 27 (4.1%) patients and correlated with right colon site, grade 2, marked intratumoral lymphocyte infiltrate and BRAF p.V600E mutation. At univariate analysis variables associated with poor OS were 10-year increase in age (p=0.001), stage IIII-IV (p=0.001), Syn ≥30% (p=0.001), infiltrative growth (p=0.04) and residual tumor R1-2 (p=0.03). At multivariable analysis, Syn expression in ≥30% of gland-forming tumor cells emerged as an independent negative prognostic factor for both OS and DFS. Moreover 10-year increase in age, stage III-IV and Syn ≥30% (p<0.001) were associated with poor OS and marked peritumoral lymphocyte infiltrate with longer OS (p=0.02). Comparable results were obtained according to DFS; in addition, right colon site (p=0.04) was associated with longer DFS while KRAS mutation (p=0.04) was associated with poor DFS at univariate analysis. MiNEN patients showed a shorter DFS than all conventional adenocarcinomas with or without Syn expression in univariate analyses (p<0,001).

Conclusions: Among conventional CRCs, we provided evidence that Syn expression is associated with worse OS and DFS and contributes to predicting clinical outcome. Future studies should explore the molecular mechanisms underlying the acquisition of the neuroendocrine phenotype to identify new targeted treatment strategies.